

Scott C Woller

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/3603417/publications.pdf](https://exaly.com/author-pdf/3603417/publications.pdf)

Version: 2025-02-01

70

PR articles

7,715

PR citations

162956

27

PR h-index

70085

69

g-index

77

documents

8757

doc citations

159291

29

h-index

9567

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Primary Care Clinicians' Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment. <i>Journal of Clinical Medicine</i> , 2024, 13, 96.	2.6	1
2	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2024, 166, 388-404.	1.1	85
3	Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent hospital-associated venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2024, 8, 102549.	0.5	0
4	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2022, 6, 1661-1670.	5.3	133
5	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. <i>BMJ Open</i> , 2022, 12, e053864.	2.0	1
6	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1910-1919.	3.9	45
7	Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12740.	0.5	2
8	A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the	0.5	3
9	D-dimer Thresholds to Exclude Pulmonary Embolism among COVID-19 Patients in the Emergency Department: Derivation with Independent Validation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, .	1.9	5
10	Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation) <i>Tj ETQq0 0 0 rgBT1/0verlock210 Tf 50 3</i>		
11	Natural Language Processing Performance for the Identification of Venous Thromboembolism in an Integrated Healthcare System. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, .	1.9	25
12	Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 90, 787-796.	2.6	28
13	Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. <i>American Journal of Emergency Medicine</i> , 2021, 41, 80-83.	1.7	7
14	Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12560.	0.5	7
15	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 153, 58-64.	1.9	6
16	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2021, 160, e545-e608.	1.1	833
17	Executive Summary. <i>Chest</i> , 2021, 160, 2247-2259.	1.1	356
18	Timing of parenteral anticoagulation after thrombolysis for the treatment of pulmonary embolism. <i>Thrombosis Research</i> , 2020, 195, 58-61.	2.4	2

#	ARTICLE	IF	PR CITATIONS
19	Predicting postdischarge hospital-associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 872-878.	0.5	3
20	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.8	117
21	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.9	123
22	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2245-2252.	3.9	10
23	Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. <i>Blood Advances</i> , 2020, 4, 2557-2566.	5.3	28
24	Choosing ultrasound technique for suspected deep vein thrombosis: which is best?. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1418-1421.	1.5	1
25	Diagnostic yield of pulmonary embolism testing in patients presenting to the emergency department with syncope. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 263-268.	0.5	5
26	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 834.	17.2	12
27	Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation. <i>European Heart Journal</i> , 2019, 40, 1538-1540.	2.1	2
28	Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-EDVT): Methods of a prospective single-arm management study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 340-348.	0.5	18
29	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. <i>Clinical Cardiology</i> , 2019, 42, 506-512.	2.1	18
30	Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization. <i>Chest</i> , 2018, 154, 249-256.	1.1	73
31	Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: A double-blind, randomized, pilot study. <i>Surgery</i> , 2018, 164, 144-149.	1.8	16
32	Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism. <i>Chest</i> , 2018, 153, 1153-1159.	1.1	8
33	Comparative thrombosis risk of vascular access devices among critically ill medical patients. <i>Thrombosis Research</i> , 2018, 172, 54-60.	2.4	20
34	Electronic alerts, comparative practitioner metrics, and education improve thromboprophylaxis and reduce venous thrombosis in community hospitals. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 481-489.	0.5	16
35	Age-adjusted versus clinical probability-adjusted D-dimer to exclude pulmonary embolism. <i>Thrombosis Research</i> , 2018, 167, 15-19.	2.4	15
36	Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. <i>American Heart Journal</i> , 2017, 188, 93-98.	3.0	43

#	ARTICLE	IF	PR CITATIONS
37	The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 75-82.	1.9	5
38	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1115.	17.2	221
39	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) initiative: A summary and review of peripherally inserted central catheter and venous catheter appropriate use. <i>Journal of Hospital Medicine</i> , 2016, 11, 306-310.	1.4	39
40	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 118, 210-214.	1.9	146
41	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. <i>Journal of the American College of Radiology</i> , 2016, 13, R18-R24.	2.3	30
42	Electronic Alerts, Comparative Practitioner Metrics, and Education Improves Thromboprophylaxis and Reduces Thrombosis. <i>American Journal of Medicine</i> , 2016, 129, 1124.e17-1124.e26.	2.3	18
43	Atrial Fibrillation Patients Treated With Long-term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-term Warfarin for Other Indications. <i>Journal of the American Heart Association</i> , 2016, 5, .	4.3	48
44	Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 239-247.	1.9	91
45	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 154-164.	2.1	290
46	Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 231-241.	2.0	1
47	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2016, 149, 315-352.	1.1	4,518
48	Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 265-273.	1.9	19
49	Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study. <i>Cardiology Research and Practice</i> , 2015, 2015, 1-10.	1.5	3
50	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-term Risk of Dementia. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 1180-1186.	2.1	43
51	The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities. <i>American Journal of Medicine</i> , 2015, 128, 986-993.e1.	2.3	84
52	Computerized Clinical Decision Support Improves Warfarin Management and Decreases Recurrent Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 197-203.	1.9	14
53	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. <i>Journal of the American College of Radiology</i> , 2014, 11, 378-383.	2.3	101
54	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. <i>Heart Rhythm</i> , 2014, 11, 2206-2213.	2.7	144

#	ARTICLE	IF	PR CITATIONS
55	Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 665-672.	1.9	29
56	Assessment of the Safety and Efficiency of Using an Age-Adjusted D-dimer Threshold to Exclude Suspected Pulmonary Embolism. <i>Chest</i> , 2014, 146, 1444-1451.	1.1	34
57	Adherence to PIOPED II Investigators' Recommendations for Computed Tomography Pulmonary Angiography. <i>American Journal of Medicine</i> , 2013, 126, 36-42.	2.3	72
58	Withholding Anticoagulation Following a Single Negative Whole-Leg Ultrasound in Patients at High Pretest Probability for Deep Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 79-85.	1.9	8
59	Reduction of Peripherally Inserted Central Catheter-Associated DVT. <i>Chest</i> , 2013, 143, 627-633.	1.1	94
60	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). <i>Circulation</i> , 2012, 125, 1997-2005.	25.3	220
61	Radiation and Chest CT Scan Examinations. <i>Chest</i> , 2012, 142, 750-760.	1.1	120
62	The Reply. <i>American Journal of Medicine</i> , 2012, 125, e25-e26.	2.3	1
63	Diagnosis and management of upper extremity deep-vein thrombosis in adults. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1097-1108.	4.2	132
64	Derivation and Validation of a Simple Model to Identify Venous Thromboembolism Risk in Medical Patients. <i>American Journal of Medicine</i> , 2011, 124, 947-954.e2.	2.3	120
65	Treatment of Chronic Lead Toxicity With Succimer. <i>American Journal of Forensic Medicine and Pathology</i> , 2011, 32, 236-238.	0.7	7
66	Risk of Deep Vein Thrombosis Following a Single Negative Whole-Leg Compression Ultrasound. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 438.	17.2	190
67	Risk of Symptomatic DVT Associated With Peripherally Inserted Central Catheters. <i>Chest</i> , 2010, 138, 803-810.	1.1	240
68	Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis.. <i>Blood</i> , 2009, 114, 243-243.	4.2	1
69	The use of a fixed high sensitivity to evaluate five D-dimer assays' ability to rule out deep venous thrombosis: a novel approach. <i>British Journal of Haematology</i> , 2005, 131, 341-347.	2.4	8
70	Hepatic epithelioid hemangioendothelioma presenting as liver infarction. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, A20.	6.3	4